NovoCure Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.7%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$725.8Mnext fiscal year
FY EPS (est.)
-$1.25next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| ASTRO 2026 Annual Meeting (TRIDENT Trial Full Dataset Presentation) | 25 Oct 2026 |
| Q3 2026 Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Total Net Revenues Quarterly174.1MTarget: 690000000 - 710000000
Active Patient Count Growth Quarterly900.0%Target: Mid-single digit growth for Optune Gio
Gross Margin Quarterly7,800.0%Target: Mid-70s percent
Adjusted EBITDA Quarterly-300KTarget: -15000000 to 0
Watch Items
- Optune Pax Commercial Launch and Payer CoverageTrigger: Elevance Health coverage policy issued; 169 prescriptions and 90 patient starts in first 7 weeksAction: Monitor expansion of commercial payer coverage and patient onboarding velocity to validate pancreatic cancer market opportunity.
- KEYNOTE D58 Phase 3 Trial EnrollmentTrigger: Full enrollment expected by Q4 2026Action: Track clinical trial recruitment progress and milestone updates for newly diagnosed GBM.
- FDA Premarket Approval for Brain Metastases from NSCLCTrigger: FDA decision expected in Q4 2026Action: Monitor regulatory feedback and potential commercial launch preparation for the brain metastases indication.
Research as of 20 Jun 2026